# Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

> **NCT03091751** · PHASE2 · COMPLETED · sponsor: **Grifols Biologicals, LLC** · enrollment: 13 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** BeneFIX

## Key facts

- **NCT ID:** NCT03091751
- **Lead sponsor:** Grifols Biologicals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091751, "Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03091751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*